The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit. The study analyzes Ly6Ehi neutrophils in biological samples from patients treated with immune checkpoint inhibitors to evaluate their likelihood of benefiting from treatment. Blood samples are collected prior to treatment and used to support the ongoing development of the algorithm.
Male or female aged at least 18 years
ECOG PS: 0/1-2
Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of the first dose of treatment.
For NSCLC: presence of activating EGFR, ALK, ROS1, RET, NTRK alterations linked to an approved first-line targeted drug.
OncoHost Ltd.
Lead sponsor
European Institute of Oncology
Collaborator
University Hospital Heidelberg
Collaborator
Hospital Universitario Virgen Macarena
Collaborator